Why the study?
COVID-19 is associated with acute myocardial infarction, but the outcomes of 30-day readmissions for MI among survivors of COVID-19 hospitalization remained to be evaluated.
Among survivors of COVID-19 hospitalization, 30-day readmission for MI is relatively rare (0.6%) but represents a significant source of mortality, accounting for 12% of all-cause readmission mortality.
Answers are grounded in this paper and cite their sources.
MI readmissions drive notable post-COVID mortality and costs; leaves open whether surveillance or prevention alters outcomes in survivors.
Background: COVID-19 is known to be associated with acute myocardial infarction (MI). Objectives: The purpose of this study was to evaluate the outcomes of 30-day readmissions for MI among survivors of COVID-19 hospitalization. Methods and Results: We used the U.S. Nationwide Readmission Database to identify COVID-19 admissions from April 1, 2020, to November 30, 2020, using International Classification of Diseases-10th Revision-Clinical Modification (ICD-10-CM) claims. The primary outcome was 30-day readmission incidence for MI. A total of 521,251 cases of COVID-19 were included, of which 11.6% were readmitted within 30 days of discharge. The 30-day readmission incidence for MI was 0.6%. The 30-day all-cause readmission mortality incidence was 1.3%. Patients readmitted for MI were more frequently males (61.6% vs 38.4%) and had a higher Charlson comorbidity burden score (7 vs 4). The most common diagnosis among 30-day MI readmission was type 2 MI (51.1%), followed by a diagnosis of a type 1 non-ST-segment elevation MI (41.7%). ST-segment elevation MI cases constituted 7.6% of all MI-readmission whereas 0.6% of patients had unstable angina. 30-day MI readmissions with a recurrent diagnosis of COVID-19 had higher readmission mortality and incidence of complications. Conversely, the odds of performing revascularization procedures were lower for MI with recurrent COVID-19. Furthermore, MI readmissions with recurrent COVID-19 had a higher length of stay (7 vs 5 days) and cost of hospitalization ($18,398 vs $16,191) when compared with non-COVID-19 MI readmissions. Conclusions: Among survivors of COVID-19 hospitalization, 5.2% of all-cause 30-day readmissions and 12% of all-cause readmission mortality were attributed to MI. MI-related readmissions were a significant source of mortality, morbidity, and resource utilization.
No takes yet. Share an insight, caveat, or question.
Zahid et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: